Zimmer Biomet Holdings Inc (ZBH)
適正価値ファンダメンタル
63
株価
$88.83
時価総額
$17.48B
パート1 · 企業の価値
概要
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$8.51B
直近12か月（2026/6/30まで）
純利益
$807M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$1.47B
自己資本合計
$12.70B
負債合計
$10.39B
流動比率
1.69
利払い倍率
4.17
負債/EBITDA
3.41
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$110.62
現在株価
$88.83
安全マージン
+19.7%
適正価値レンジ
$71.91 - $149.34
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
21.56
ROE
5.6%
P/B レシオ
1.34
P/FCF
11.12
粗利益率
69.9%
ROIC
4.8%
収益性レーダー
価値創造（経済的モート）
ROIC
4.8%
WACC
6.5%
ROIC − WACC
-1.7 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（16）
- EPS shows upward trend
- Gross Margin 69.9%
- P/FCF 11.12
- P/B Ratio 1.34
- Debt/Equity ratio
- Operating Margin 14.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Earnings Surprise avg 3.4%
- Earnings Quality (OCF/NI) 2.16
- Share Dilution -2.6%
- Piotroski F-Score 5/9
不合格（10）
- EPS CAGR 0.47%
- Price CAGR -0.69%
- ROIC 4.8%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- ROE 6.3%
- Revenue Growth 5Y 3.2%
- Analyst Consensus 33% Buy
- Net Margin Trend 9.5% vs 10.5%
データなし（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Ivan Tornos | President, CEO & Chairman of the Board | 50 |
| Mr. Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 55 |
| Mr. JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 43 |
| Mr. Kevin R. Thornal | Group President of Global Businesses & Americas | 51 |
| Mr. Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 50 |
| Mr. Shaun Braun | Senior VP & Chief Information and Technology Officer | - |
| Dr. Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | - |
| Mr. David M. DeMartino | Senior Vice President of Investor Relations | - |
| Mr. Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 53 |
| Ms. Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | - |
監査リスク
6
取締役会リスク
8
報酬リスク
8
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for ZBH, sourced from Markets Gazette.